About WUXI BIO Company

The Group is the world's leading open biopharmaceutical CRDMO, providing end-to-end solutions for the discovery, development and production of biopharmaceuticals. Biopharmaceuticals are a subcategory of pharmaceuticals, revolutionizing disease treatment methods in many major treatment fields around the world. The Group's end-to-end CRDMO service platform enables it to provide services covering the entire biopharmaceutical development process and to provide customers with customized solutions according to their respective service requirements at any stage of the biopharmaceutical development process. The biopharmaceutical development process generally covers five stages: (i) drug discovery, (ii) preclinical development, (iii) early (phase I and II) clinical development, (iv) late stage (phase III) clinical development, and (v) commercial production. The services required for the biopharmaceutical development process can be divided into two categories: (1) pre-IND services, which include services provided in the first two stages of the biopharmaceutical development process, and (2) post-IND services, which include services provided in the remaining three stages of the biopharmaceutical development process. The Group's business model is based on its “follow and win elements” strategy. Customer demand for the Group's services generally increases as their biopharmaceuticals advance through the biopharmaceutical development process and eventually achieve commercial production. Therefore, the Group's revenue from each integrated project usually increases as the project progresses.